Diagnostic and Management Pathways for Pulmonary Carcinoid Tumours in the United Kingdom: Results from the National Lung Neuroendocrine Tumour Pathway Project

Table 1

Proportion of respondents who would consider offering each type of adjuvant treatment to patients with TC or AC following surgical resection.

PC type/stage	Treatments for patients with typical carcinoid tumours, no. (%) of respondents (n = 27)					Treatments for patients with atypical carcinoid tumours, no. (%) of respondents (n = 27)
	SSA	CT	RT	Treatment may be considered	Any type of treatment^#	SSA	CT	RT	Treatment may be considered	Any type of treatment^#
N0 M0	0 (0%)	0 (0%)	0 (0%)	1 (4%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)	1 (4%)
N1 M0	1 (4%)	0 (0%)	1 (4%)	3 (11%)	4 (15%)	2 (7%)	6 (22%)	2 (7%)	3 (11%)	9 (33%)
N2-3 M0	3 (11%)	2 (7%)	3 (11%)	3 (11%)	8 (30%)	2 (7%)	9 (33%)	2 (7%)	3 (11%)	13 (48%)
R1 resected	4 (15%)	2 (7%)	7 (26%)	2 (7%)	11 (41%)	3 (11%)	5 (19%)	7 (26%)	1 (4%)	13 (48%)

Treatment types not mutually exclusive. Respondents who stated that the patient’s suitability for adjuvant treatment may be discussed with the multidisciplinary team (or other specialist), but did not specify a particular type of treatment. ^#Proportion of respondents who reported that they would consider any form of adjuvant treatment (including those who stated that the patient’s suitability for treatment may be discussed with the multidisciplinary team [or other specialist]). CT: chemotherapy; PC: pulmonary carcinoid; RT: radiotherapy; and SSA: somatostatin analogue.